Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DPV 001

Next Previous
Drug Profile

DPV 001

Alternative Names: Autologous DRibble vaccine; Autophagosome cancer vaccine - UbiVac; Cancer vaccine DRibble; DPV-001; DRibble Vaccine

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UbiVac
  • Developer Bristol-Myers Squibb; National Cancer Institute (USA); Providence Health & Services; UbiVac
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Preclinical Gastric cancer; Oesophageal cancer
  • Suspended Triple negative breast cancer
  • No development reported Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (Parenteral)
  • 28 Jul 2025 No recent reports of development identified for preclinical development in Pancreatic-cancer(Combination therapy) in USA (Parenteral)
  • 06 Apr 2024 Adverse events and efficacy data from phase I trial in Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) released by company

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top